Qiagen to Pay 2% Coupon Rate on $750 Million Net Share Settled Convertible Bonds
ByAinvest
Thursday, Aug 28, 2025 12:25 pm ET1min read
QGEN--
Qiagen NV specializes in providing Sample to Insight solutions that transform biological samples into molecular insights. These solutions integrate sample and assay technologies, bioinformatics, and automation systems. The company's sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from various materials. Assay technologies make these biomolecules visible for analysis, such as identifying genetic information or gene mutations. Bioinformatics solutions interpret data to provide actionable insights. Automation platforms, based on technologies like polymerase chain reaction (PCR) and next-generation sequencing (NGS), tie these components together in molecular testing workflows [2].
The net proceeds from this bond issuance will be used for general corporate purposes, including refinancing existing debt. This strategic move allows Qiagen NV to strengthen its financial position and potentially invest in growth opportunities.
References:
1. [1] https://seekingalpha.com/news/4489845-qiagen-to-raise-750m-via-non-us-offering-of-convertible-bonds
2. [2] https://www.marketscreener.com/news/qiagen-announces-placement-of-new-net-share-settled-convertible-bonds-ce7c50dcd88cf325
Qiagen NV, a Dutch holding company, has settled $750 million net share convertible bonds with a 2% coupon rate. The company provides Sample to Insight solutions that transform biological samples into molecular insights through sample and assay technologies, bioinformatics, and automation systems. The solutions integrate sample and assay technologies, bioinformatics, and automation systems to transform biological samples into molecular insights.
Qiagen NV, a Dutch holding company, has settled $750 million in net share convertible bonds with a 2% coupon rate. This private placement is exclusively targeted at institutional investors outside the U.S., Canada, Australia, Japan, and South Africa [1]. The bonds, which have a minimum denomination of $200,000, will be issued in an aggregate volume of $750 million. The underlying shares amount to approximately 11.2 million, representing about 5.1% of the company's current issued and outstanding share capital [1].Qiagen NV specializes in providing Sample to Insight solutions that transform biological samples into molecular insights. These solutions integrate sample and assay technologies, bioinformatics, and automation systems. The company's sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from various materials. Assay technologies make these biomolecules visible for analysis, such as identifying genetic information or gene mutations. Bioinformatics solutions interpret data to provide actionable insights. Automation platforms, based on technologies like polymerase chain reaction (PCR) and next-generation sequencing (NGS), tie these components together in molecular testing workflows [2].
The net proceeds from this bond issuance will be used for general corporate purposes, including refinancing existing debt. This strategic move allows Qiagen NV to strengthen its financial position and potentially invest in growth opportunities.
References:
1. [1] https://seekingalpha.com/news/4489845-qiagen-to-raise-750m-via-non-us-offering-of-convertible-bonds
2. [2] https://www.marketscreener.com/news/qiagen-announces-placement-of-new-net-share-settled-convertible-bonds-ce7c50dcd88cf325

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet